We have located links that may give you full text access.
Infectious complications of immune modulatory agents.
Current Infectious Disease Reports 2013 December
Immune modulatory agents used in solid organ transplantation and other disciplines have various mechanisms of action and differences in the duration and intensity of immunosuppression. While newer agents have improved patient outcomes, an important result of these immune modulatory agents is associated infections, caused by organisms such as cytomegalovirus, BK polyomavirus, Epstein-Barr virus and tuberculosis. Herein, we review the infectious complications of several newer immune modulatory drugs-belatacept, alemtuzumab, and rituximab-and focus on their use in solid organ transplantation. New immune modulatory agents can potentially modify the landscape of allograft rejection and noninfectious and infectious complications. Health-care practitioners should remain familiar with these agents and their potential infectious complications to help ensure optimal patient outcomes.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app